<DOC>
	<DOCNO>NCT01406600</DOCNO>
	<brief_summary>Choriogonadotropin alfa ( Ovidrel® ) recombinant hCG ( rhCG ) preparation derive genetically engineer Chinese hamster ovary cell , widely use final oocyte maturation trigger assist reproductive technology ( ART ) .Recombinant hCG investigate safety efficacy compare urinary hCG , still optimal dose rhCG questionable . From former study , proven high dose hCG make ovarian hyperstimulation syndrome ( OHSS ) usual condition . On hand , hypothesize high dose hCG may improve oocyte maturity poor responder easily provoke OHSS . Hence , study assess comparative efficacy safety 250mcg 500mcg rhCG ART treatment cycle .</brief_summary>
	<brief_title>Optimal rhCG ( Ovidrel® ) Dose Poor Responder During IVF ICSI Cycles</brief_title>
	<detailed_description>Randomized prospective clinical study compare two dos rhCG ( 250mcg vs. 500mcg ) .</detailed_description>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<criteria>poor response prior IVF cycle ( ≤ 4 oocyte retrieve ) woman 's age ≥ 40 year FSH ≥ 10mIU/mL AMH ≤ 1.1ng/mL Antral follicle count &lt; 6 patient without informed consent</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>44 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>recombinant hCG</keyword>
	<keyword>poor responder</keyword>
	<keyword>oocyte maturity</keyword>
</DOC>